文献速递牙周病口腔黏膜病

结缔组织病系统性硬化症的口腔颌面部并发症

Orofacial Complications of the Connective Tissue Disease Systemic Sclerosis.
PubMed 文献 · J Dent Res · 2024-05-23

系统性硬化症(SSc)是一种病因不明的自身免疫性纤维化结缔组织病。本综述指出SSc患者因皮肤、胃肠道及口腔局部纤维化可出现小口畸形、口干、牙龈退缩等口腔并发症,并常以口腔表现为首发诊断线索,但相关研究严重不足。

要点

  • SSc患者常因口腔表现首诊于牙医,需警惕小口畸形、口干及牙龈退缩等体征。
  • SSc口腔并发症包括牙周炎、牙齿缺失、舌活动受限及营养不良,影响生活质量。
  • 伴牙周并发症的SSc患者基质金属蛋白酶-9及白细胞介素-6等趋化因子水平升高。

核心结论

  • SSc患者存在因皮肤、胃肠道及口腔纤维化导致的小口畸形、口干、牙龈退缩等显著口腔并发症,但该领域高质量研究匮乏。

研究设计与样本

  • 本文为综述,总结当前关于SSc口腔并发症的知识现状,未报告系统检索范围或样本量。

主要发现

  • SSc患者因皮肤纤维化致小口畸形,因胃肠道纤维化致酸反流,因口腔本身纤维化致口干和牙龈退缩。
  • SSc患者口腔并发症包括牙周炎、牙齿缺失、舌活动受限和营养不良,导致生活质量受损。
  • 伴牙周并发症的SSc患者基质金属蛋白酶-9及白细胞介素-6和趋化因子(C-X-C基序)配体-4等趋化因子水平升高。

临床怎么用

  • 牙医应认识SSc的口腔特征性表现,因其常为患者初诊诊断线索。
  • 对SSc患者应关注牙周状况、口干及小口畸形对口腔卫生维护的影响。

局限性

  • SSc口腔并发症研究严重不足,高质量出版物稀少。
  • 既往SSc临床试验多探讨抗炎药物抗纤维化效果,但未以口腔症状作为临床终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Scleroderma (systemic sclerosis, SSc) is an autoimmune fibrosing connective tissue disease of unknown etiology. SSc patients show increased levels of autoantibodies, profibrotic cytokines, and extracellular matrix remodeling enzymes that collectively cause activated (myo)fibroblasts, the effector cell type of fibrosis. Despite these impacts, no disease-modifying therapy exists; individual symptoms are treated on a patient-to-patient basis. SSc research has been principally focused on symptoms observed in the lung and skin. However, SSc patients display significant oral complications that arise due to fibrosis of the not only skin, causing microstomia, but also the gastrointestinal tract, causing acid reflux, and the oral cavity itself, causing xerostomia and gingival recession. Due to these complications, SSc patients have impaired quality of life, including periodontitis, tooth loss, reduced tongue mobility, and malnutrition. Indeed, due to their characteristic oral presentation, SSc patients are often initially diagnosed by dentists. Despite their clinical importance, the oral complications of SSc are severely understudied; high-quality publications on this topic are scant. However, SSc patients with periodontal complications possess increased levels of matrix metalloproteinase-9 and chemokines, such as interleukin-6 and chemokine (C-X-C motif) ligand-4. Although many unsuccessful clinical trials, mainly exploring the antifibrotic effects of anti-inflammatory agents, have been conducted in SSc, none have used oral symptoms, which may be more amenable to anti-inflammatory drugs, as clinical end points. This review summarizes the current state of knowledge regarding oral complications in SSc with the goal of inspiring future research in this extremely important and underinvestigated area.

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Sharma M, Fadl A, Leask A, et al. Orofacial Complications of the Connective Tissue Disease Systemic Sclerosis. J Dent Res. 2024. PMID: 38779873. doi:10.1177/00220345241249408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。